Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 24Genitourinary 21Other hematologic neoplasm 13Lymphoid 9Sarcoma 8Myeloid 5Gynecologic 5Gastrointestinal 5Breast 4Plasma cell 2CNS 2Tumor-Agnostic 1Other neoplasm 1NET 1Endocrine 1

Conditions

Triple Negative Breast Neoplasms 3Breast Neoplasms 2Neoplasm Metastasis 1Breast Neoplasms, Male 1Breast Carcinoma In Situ 1Brain Neoplasms 1

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 486Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 152Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interferon alpha-2 × Breast × Clear all
NCT05756166 2025-06-24

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Roswell Park Cancer Institute

Phase 1/2 Terminated
5 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04081389 2023-09-11

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Roswell Park Cancer Institute

Phase 1 Completed
9 enrolled 17 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03599453 2023-07-18

Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

Roswell Park Cancer Institute

Phase EARLY_PHASE1 Completed
8 enrolled
Breast

Triple Negative Breast Neoplasms

NCT00227656 2012-12-11

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
2 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡